

Acupuncture for the prevention of chronic migraine attacks

Submission date 11/09/2017	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 25/09/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 25/06/2024	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Approximately 1.4% to 2.2% of the general population suffers from chronic migraine (CM). This is when a headache lasts for more than 15 days a month. Acupuncture (an ancient Chinese medicine that inserts fine needles in the body) may be a choice to treat chronic migraine, when pharmacological prophylaxis (a treatment of medication) is not suitable. However, the efficacy of acupuncture has not been confirmed. The aim of this study is to evaluate the efficacy of acupuncture compared with a medication called topiramate in chronic migraine patients.

Who can participate?

Adults aged 18 to 65 who have diagnosed chronic migraines.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group receive verum acupuncture and placebo medicine in the treatment group. Those in the second group are treated with sham acupuncture and medicine (topiramate). All participants are given for 3 months of treatment and 2 months of follow-up. Participants are assessed for their amount of days they experience headaches.

What are the possible benefits and risks of participating?

Participants may benefit from improvements in their chronic migraine symptoms. Participants may experience transient pain or soreness, or other possible problems including bleeding, bruising or local paresthesia (tingling) around the spot of the needle. During the topiramate titration and maintenance period, participants may experience paresthesia, difficulty with memory, dyspepsia (indigestion), fatigue, dizziness, somnolence (sleepiness) and nausea.

Where is the study run from?

Beijing Hospital of Traditional Chinese Medicine (China)

When is the study starting and how long is it expected to run for?

July 2017 to December 2022

Who is funding the study?
Beijing Municipal Science & Technology Commission (China)

Who is the main contact?

1. Dr Bin Li
libin@bjzhongyi.com
2. Dr Lu Liu
liu_lu1985@aliyun.com

Contact information

Type(s)

Public

Contact name

Dr Bin Li

Contact details

Beijing Hospital of Traditional Chinese Medicine
Capital Medical University
Beijing Dongcheng District Backstreet Gallery No.23
Beijing
China
100010
+86 18910781852
libin@bjzhongyi.com

Type(s)

Public

Contact name

Dr Lu Liu

Contact details

Beijing Dongcheng District Backstreet Gallery No.23
Beijing
China
100010
+86 13520788752
liu_lu1985@aliyun.com

Additional identifiers

Protocol serial number

Z171100001017033

Study information

Scientific Title

Acupuncture as prophylaxis for chronic migraine: A single-blinded, double-dummy, randomised controlled trial

Study objectives

The aim of this study is to evaluate the efficacy of acupuncture compared with topiramate in chronic migraine patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, 21/07/2017, ref: 2017BL-045-01

Study design

This is a single-blind, randomized controlled clinical trial. A total of 60 participants will be randomly assigned to two different groups. Participants will receive verum acupuncture and placebo medicine in the treatment group, while participants in the control group will be treated with sham acupuncture and medicine (topiramate). All participants will be given for 3 months of treatment and 2 months of follow-up.

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic migraine (CM)

Interventions

Participants receive verum acupuncture and placebo medicine in the treatment group, while participants in the control group are treated with sham acupuncture and medicine (topiramate). All participants are given 3 months of treatment and 2 months of follow-up.

The central randomization is performed by the Research Center of Clinical Epidemiology affiliated to Peking University in China, which use block randomization to generate the random allocation sequence and prepare predetermined computer made randomization opaque sealed envelopes. The envelopes are numbered consecutively and connected into a strain. Each envelope is separated from the strain and then opened in sequence only after baseline period when the participants are registered in the trial. In our study, the participants are informed that they have a 50% chance of being allocated in either of the two groups: verum acupuncture and placebo medicine group and sham acupuncture and medicine (topiramate).

Treatment group: In the treatment group, verum acupuncture treatment consists of three 30-minute sessions per week, administered over 12 weeks, and placebo medication was taken for 12 consecutive weeks. The acupuncture points, including both obligatory and additional points, are selected based on the consensus of clinical experiences of acupuncture experts. The obligatory points include DU20 (Baihui), DU24 (Shenting), GB13 (Benshen), GB8 (Shuaigu), and GB20 (Fengchi). Additional points can be chosen according to syndrome differentiation of meridians: Shaoyang headache (TE-GB): SJ5 (Waiguan), GB34 (Yanglingquan); Yangming

headache (LI-ST): LI4 (Hegu), ST44 (Neiting); Taiyang headache (SI-BL): BL60 (Kunlun), SI3 (Houxi); Jueyin headache (PC-LR): LR3 (Taichong), GB40 (Qiu Xu); Needles are inserted in an appropriate angle to a depth of 10-15 mm and manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as "De Qi" (feeling of needle sensation refers to tenseness around the needle felt by the practitioner and numbness, distension, soreness, and heaviness around the point felt by the patient). Needles are stimulated manually at least 10 s, then the needles are retained for 30 minutes.

Control group:

The control group is treated with topiramate and three 30-minute sessions of sham acupuncture treatment per week for 12 weeks. Both topiramate and placebos are taken for 12 consecutive weeks. The placebo medicine have exactly the same appearance as true medicines (topiramate). The treatment phase consisted of a 4-week titration period and an 8-week maintenance period. During the titration period, participants are given topiramate 25 mg/day at bedtime for 1 week, followed by weekly increases of 25 mg up to either 100 mg/day of topiramate or to the maximal tolerated dose. Starting in week 2, topiramate are given daily in equally divided twice daily doses. During the maintenance period, a stable topiramate dose of at least 50 mg/ day is required.

The sham points, including 2 points on the arms and 3 points on the legs, are defined as unrelated to headache based on a vast amount of TCM reference books and the consensus of clinical experiences of acupuncture experts. The sham points include LI15 (Jiangu), PC3 (Qizhe), GB35 (Yangjiao), LR7(Xiguan), and ST37 (Shangjuxu). Needles are inserted 10-15 mm in depth and manually manipulated with rotation methods to produce a characteristic sensation known as "De Qi". Technique of mild reinforcing and attenuating is applied, and the needles are retained for 30 minutes.

All participants are permitted to treat acute headaches as required, Ibuprofen was recommended to all patients as their first choice for acute medication. The name and dosage of these medications are required to be recorded in the headache diaries.

Intervention Type

Other

Primary outcome(s)

Monthly number of headache days (any intensity) is measured using the headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks.

Key secondary outcome(s)

1. Number of days with acute headache medications is measured using headache diary at baseline period (4 weeks before the beginning of treatment) and 12 weeks.
2. Migraine Disability is measured using the MIDAS score at baseline, 12 weeks, and 24 weeks.
3. Migraine-Specific Quality-of-Life Questionnaire/Headache impact test measured using the MSQ/HIT6 questionnaire at baseline, 12 weeks, and 24 weeks.
4. Anxiety is measured using the STAI/BDI-II questionnaires at baseline, 12 weeks, and 24 weeks.

Completion date

07/12/2022

Eligibility

Key inclusion criteria

1. Diagnosed as chronic migraine according to the diagnostic criteria specified by the International Classification of Headache Disorders(International Classification of Headache Disorders-Third edition (beta version) [ICHD-β])
2. Aged between 18 and 65 years old
3. No prophylaxis treatments with acupuncture or drugs in the past 3 months
4. Written informed consent provided

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

60

Key exclusion criteria

1. Tension-type headache, cluster headache, and other primary headaches
2. Relatively severe systemic diseases(cardiovascular disease, acute infectious disease, hematopathy,endocrinopathy, allergy, and methysis)
3. Headache caused by otorhinolaryngology diseases or intracranial pathological changes
4. Secondary headache and other neurological diseases
5. Pregnancy, lactation, or insufficient contraception

Date of first enrolment

07/05/2018

Date of final enrolment

23/05/2022

Locations**Countries of recruitment**

China

Study participating centre

Beijing Hospital of Traditional Chinese Medicine

Capital Medical University

Beijing Dongcheng District Backstreet Gallery No.23

Beijing
China
100023

Sponsor information

Organisation
Beijing Hospital of Traditional Chinese Medicine

ROR
<https://ror.org/057vq6e26>

Funder(s)

Funder type
Government

Funder Name
Beijing Municipal Science & Technology Commission

Results and Publications

Individual participant data (IPD) sharing plan
The current data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		11/06/2024	25/06/2024	Yes	No
Protocol article	protocol	31/05/2018	13/05/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes